BACKGROUND: In 2007, Medtronic Sprint Fidelis defibrillator leads were taken off the market due to a high rate of @entity177 . Current data do not allow for risk stratification of @entity1 with regard to @entity177 . AIMS: We sought to determine predictors of Sprint Fidelis @entity177 . METHODS: Between 2004 and 2007, 269 Sprint Fidelis leads were implanted in 258 @entity1 in our centre. Variables associated with @entity177 were assessed by the Kaplan-Meier method and a Cox survival model. RESULTS: During a median follow-up of 2.80 years (maximum 5.32), we observed 33 (12.3%) Sprint Fidelis lead failures (5-year survival, 65.6%    7.5%). In univariate analysis, age was the only predictor of @entity177 (hazard ratio [HR] for 1-year increase 0.97; 95% confidence interval [CI] 0.95-0.99; p=0.009). @entity1 aged<62.5 years (median) had a significantly increased risk of @entity177 compared with @entity1 aged>62.5 years (HR 2.80; CI 1.30-6.02; p=0.009). Survival without Sprint Fidelis @entity177 was 55.6%    10.4%) in @entity1 aged<62.5 years (24/134 leads) vs 78.6%    8.8% in @entity1 aged>62.5 years (9/135 leads). The annual incidence of @entity177 in @entity1 aged<62.5 years was 11.6%    4.9% during the fourth year after implantation and 22.9%    13.2% during the fifth year. CONCLUSION: Overall, we found a higher rate of Sprint Fidelis lead dysfunction than previously described. Lead failure was much more frequent in younger @entity1 . Our results emphasize the need for close follow-up of younger @entity1 with Sprint Fidelis leads and suggest that, in these @entity1 , the implantation of a new implantable cardioverter defibrillator lead at the time of generator replacement might be reasonable.

Risk of Sprint Fidelis defibrillator XXXX is highly dependent on age.

@entity177 :: ('MESH:D051437', 'Disease') :: ['lead failure'] @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']
@entity177 :: (MESH:D051437,Disease) :: ['lead failure']
